Nolasiban: Ph III IMPLANT2 started

ObsEva began the double-blind, placebo-controlled, European Phase III IMPLANT2 trial to evaluate single doses of 900 mg oral nolasiban before fresh embryo transfer on day 3 or day 5 following egg retr...